Magenta Therapeutics

General Information
Business:

 

For more than 50 years, doctors and patients have had difficult conversations about bone marrow transplant: the procedure can save patients’ lives and cure them of disease, but the risk of toxicity and even mortality is often a significant deterrent. At Magenta, we believe we can refocus that conversation on the cure and enable many more patients with devastating diseases such as severe autoimmune diseases, including multiple sclerosis; blood cancers, including leukemia; and genetic diseases such as sickle cell disease to benefit from advances in transplant medicine.

 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 48
Founded: 2015
Contact Information
Address 50 Hampshire Street, Cambridge, MA 02139, US
Phone Number (857) 242-0170
Web Address http://www.magentatx.com
View Prospectus: Magenta Therapeutics
Financial Information
Market Cap $515.6mil
Revenues $0 mil (last 12 months)
Net Income $-41.5 mil (last 12 months)
IPO Profile
Symbol MGTA
Exchange NASDAQ
Shares (millions): 6.7
Price range $15.00 - $15.00
Est. $ Volume $100.0 mil
Manager / Joint Managers J.P. Morgan/ Goldman Sachs/ Cowen
CO-Managers Wedbush PacGrow
Expected To Trade: 6/21/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change